Hematologic Malignancies/leadingdiscoveries.aacr.org
Jan 15, 2025, 08:14
Chokri Ben Lamine: Immune Targets in Hematologic Malignancies
Chokri Ben Lamine, Adult Hematology and stem cell transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital & Research Center, shared a post on X:
“Immune Targets in Hematologic Malignancies:
- B-cell Leukemia/Lymphoma: Key targets include CD19, CD20, CD22, and CD30, paving the way for innovative therapies like CAR-T and monoclonal antibodies.
- Multiple Myeloma (MM): Groundbreaking advancements focus on BCMA, CD38, CS1, and emerging targets like GPRC5D and APRIL, offering hope for refractory cases.
- Acute Myeloid Leukemia (AML): Precision therapies targeting CD123, FLT3, CD33, and CLL-1 are reshaping outcomes for patients with high-risk disease.
- Hodgkin Lymphoma (HL): Iconic targets such as CD30 and CD70 remain at the forefront of immunotherapy strategies.
- T-cell Leukemia/Lymphoma: Novel agents are designed against CD5, CD7, CD99, and TRBC1, enhancing options for these challenging diseases.”
More posts featuring Chokri Ben Lamine.
Acute Myeloid Leukemia
AML
cancer
Chokri Ben Lamine
fight against cancer
Global fight against cancer
hematologic malignancies
Hodgkin lymphoma
Immune Targets
King Faisal Specialist Hospital & Research Center
lymphoma
monoclonal antibodies
multiple myeloma
OncoDaily
Oncology
Oncology Center
T-cell leukemia
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 15, 2025, 08:14
Jan 15, 2025, 07:53
Jan 15, 2025, 07:27
Jan 15, 2025, 07:22
Jan 15, 2025, 07:07
Jan 15, 2025, 06:56